To the best of our knowledge, this is the first study that has identified the genetic profile of CYP2D6 and evaluated the speculated association between CYP2D6 genotype and clinical outcomes of adjuvant tamoxifen therapy in a cohort of Syrian breast cancer patients. This evidence concerns the gene CYP2D6 and breast cancer.